Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by DIANA BELL and RENATA FERRAROTTO.
DIANA BELL
Connection Strength
5.627
RENATA FERRAROTTO
  1. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma. Head Neck. 2018 08; 40(8):1676-1684.
    View in: PubMed
    Score: 0.626
  2. Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors. Clin Cancer Res. 2023 08 15; 29(16):3162-3171.
    View in: PubMed
    Score: 0.227
  3. Correction: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res. 2023 Jul 14; 29(14):2737.
    View in: PubMed
    Score: 0.226
  4. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. J Clin Oncol. 2023 05 20; 41(15):2843-2851.
    View in: PubMed
    Score: 0.221
  5. Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma. Oral Oncol. 2023 03; 138:106311.
    View in: PubMed
    Score: 0.219
  6. Optimal Combination of Neuroendocrine Markers for the Detection of High-Grade Neuroendocrine Tumors of the Sinonasal Tract and Lung. Curr Oncol Rep. 2023 01; 25(1):1-10.
    View in: PubMed
    Score: 0.216
  7. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735.
    View in: PubMed
    Score: 0.207
  8. Spontaneous tumor regression following COVID-19 vaccination. J Immunother Cancer. 2022 03; 10(3).
    View in: PubMed
    Score: 0.206
  9. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer. 2022 02 01; 128(3):509-518.
    View in: PubMed
    Score: 0.200
  10. Therapeutic approaches and outcomes in patients with larynx or hypopharynx high-grade neuroendocrine carcinoma: A single-center retrospective analysis. Head Neck. 2021 12; 43(12):3788-3795.
    View in: PubMed
    Score: 0.199
  11. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase?II Trial. Adv Ther. 2021 08; 38(8):4581-4591.
    View in: PubMed
    Score: 0.197
  12. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
    View in: PubMed
    Score: 0.196
  13. The tumor immune contexture of salivary duct carcinoma. Head Neck. 2021 04; 43(4):1213-1219.
    View in: PubMed
    Score: 0.191
  14. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res. 2021 02 01; 27(3):852-864.
    View in: PubMed
    Score: 0.188
  15. von Ebner's glands intercalated duct adenocarcinoma with PALB2 gene mutation. Ann Diagn Pathol. 2020 Dec; 49:151637.
    View in: PubMed
    Score: 0.187
  16. High-grade sinonasal carcinomas and surveillance of differential expression in immune related transcriptome. Ann Diagn Pathol. 2020 Dec; 49:151622.
    View in: PubMed
    Score: 0.186
  17. Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. Clin Cancer Res. 2020 07 01; 26(13):3211-3219.
    View in: PubMed
    Score: 0.180
  18. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2020 02; 101:104523.
    View in: PubMed
    Score: 0.177
  19. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland. Virchows Arch. 2020 Feb; 476(2):295-305.
    View in: PubMed
    Score: 0.173
  20. Magnifying glass on spiradenoma and cylindroma histogenesis and tumorigenesis using systematic transcriptome analysis. Ann Diagn Pathol. 2019 Aug; 41:14-23.
    View in: PubMed
    Score: 0.169
  21. PD-L1 expression by immunohistochemistry in salivary duct carcinoma. Ann Diagn Pathol. 2019 Jun; 40:49-52.
    View in: PubMed
    Score: 0.168
  22. Salivary gland tumors: Molecular characterization and therapeutic advances for metastatic disease. Head Neck. 2019 01; 41(1):239-247.
    View in: PubMed
    Score: 0.165
  23. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017 Jan 20; 35(3):352-360.
    View in: PubMed
    Score: 0.143
  24. Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland. Cancer Biol Ther. 2015; 16(6):834-8.
    View in: PubMed
    Score: 0.128
  25. Long-term outcomes of modern multidisciplinary management of sinonasal cancers: The M. D. Anderson experience. Head Neck. 2023 07; 45(7):1692-1703.
    View in: PubMed
    Score: 0.056
  26. Deep learning-based pathology image analysis predicts cancer progression risk in patients with oral leukoplakia. Cancer Med. 2023 03; 12(6):7508-7518.
    View in: PubMed
    Score: 0.055
  27. Multifocal regression and pathologic response predicts recurrence after neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Oral Oncol. 2021 11; 122:105520.
    View in: PubMed
    Score: 0.050
  28. Long-Term Outcomes of Olfactory Neuroblastoma: MD Anderson Cancer Center Experience and Review of the Literature. Laryngoscope. 2022 02; 132(2):290-297.
    View in: PubMed
    Score: 0.049
  29. Delay to surgery after neoadjuvant chemotherapy in head and neck squamous cell carcinoma affects oncologic outcomes. Cancer. 2021 06 15; 127(12):1984-1992.
    View in: PubMed
    Score: 0.048
  30. Clinical Implication of Diagnostic and Histopathologic Discrepancies in Sinonasal Malignancies. Laryngoscope. 2021 05; 131(5):E1468-E1475.
    View in: PubMed
    Score: 0.047
  31. Oncogenic Orphan Nuclear Receptor NR4A3 Interacts and Cooperates with MYB in Acinic Cell Carcinoma. Cancers (Basel). 2020 Aug 27; 12(9).
    View in: PubMed
    Score: 0.046
  32. Prognostic factors for local recurrence and survival and impact of local treatments on survival in lacrimal gland carcinoma. Br J Ophthalmol. 2021 06; 105(6):768-774.
    View in: PubMed
    Score: 0.046
  33. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135.
    View in: PubMed
    Score: 0.045
  34. Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma. J Clin Oncol. 2019 02 20; 37(6):504-512.
    View in: PubMed
    Score: 0.041
  35. Prognostic factors and survival in adenoid cystic carcinoma of the sinonasal cavity. Head Neck. 2018 12; 40(12):2596-2605.
    View in: PubMed
    Score: 0.041
  36. Early Stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb. Laryngoscope. 2018 06; 128(6):1274-1280.
    View in: PubMed
    Score: 0.038
  37. Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck. 2017 08; 39(8):1671-1679.
    View in: PubMed
    Score: 0.037
  38. Molecular characteristics and potential therapeutic targets in Merkel cell carcinoma. J Clin Pathol. 2016 May; 69(5):382-90.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.